Researchers have discovered and validated a blood test that can predict with greater than 90 percent accuracy if a healthy person will develop mild cognitive impairment or Alzheimer’s disease within three years.
Described in the April issue of Nature Medicine, the study heralds the potential for developing treatment strategies for Alzheimer’s at an earlier stage, when therapy would be more effective at slowing or preventing onset of symptoms. It is the first known published report of blood-based biomarkers for preclinical Alzheimer’s.
The test identifies 10 lipids, or fats, in the blood that predict disease onset. It could be ready for use in clinical studies in as few as two years and, researchers say, other diagnostic uses are possible.
“Our novel blood test offers the potential to identify people at risk for progressive cognitive decline and can change how patients, their families and treating physicians plan for and manage the disorder,” says the study’s corresponding author Howard J. Federoff, MD, PhD, professor of neurology and executive vice president for health sciences at Georgetown University Medical Center.
There is no cure or effective treatment for Alzheimer’s. Worldwide, about 35.6 million individuals have the disease and, according to the World Health Organization, the number will double every 20 years to 115.4 million people with Alzheimer’s by 2050.
Federoff explains there have been many efforts to develop drugs to slow or reverse the progression of Alzheimer’s disease, but all of them have failed. He says one reason may be the drugs were evaluated too late in the disease process.
“The preclinical state of the disease offers a window of opportunity for timely disease-modifying intervention,” Federoff says. “Biomarkers such as ours that define this asymptomatic period are critical for successful development and application of these therapeutics.”
The Latest on: Alzheimer’s
[google_news title=”” keyword=”Alzheimer’s” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Alzheimer’s
- Annovis tumbles as Alzheimer's treatment misses in mid-stage studyon April 29, 2024 at 2:31 pm
Annovis Bio's on Monday reported data that showed its Alzheimer's disease drug failed to show statistical significance in meeting the goals of a mid-stage trial sending its shares tumbling as much as ...
- Annovis Bio stock price plummets following mixed results for experimental Alzheimer's treatmenton April 29, 2024 at 11:18 am
Annovis Bio shares plummeted by more than 50% Monday after the Malvern biopharmaceutical company announced mixed results from mid-stage testing of its experimental Alzheimer's disease treatment.
- Why Is Alzheimer's-Focused Annovis Bio Stock Nosediving On Monday?on April 29, 2024 at 10:53 am
Annovis Bio faces setbacks in Phase 2/3 Alzheimer's study, revealing minimal change in patients' conditions. Despite slight improvements in mild cases, results show no significant difference in ...
- Stem cells improve memory, reduce inflammation in Alzheimer's mouse brainson April 29, 2024 at 10:27 am
When people think of Alzheimer's Disease and possible treatment, amyloid—and the accumulation of plaques that invade the cerebral cortex—is often brought up first. However, scientists are finding that ...
- Annovis' shares plummet 60% on another failure for lead Alzheimer's medon April 29, 2024 at 8:44 am
Annovis Bio heralded a “significantly higher rate of improvement” in patients with Alzheimer’s disease who received buntanetap. However, digging a little deeper into the muddled readout sugges | ...
- Memories in the Making event raises funds for Alzheimer’son April 29, 2024 at 7:28 am
The Alzheimer’s Association is holding a unique art auction/fundraiser on Friday. The group’s annual Memories in the Making event is Friday, May 3 from 5:30 – 10 p.m. at the Vibrant Arena at the Mark, ...
- What Maria Shriver Wants Women to Know About Reducing Alzheimer's Disease Riskon April 29, 2024 at 7:21 am
Maria Shriver is taking on Alzheimer's disease and specifically wants women to know they are at higher risk for the condition. She has founded the Women’s Alzheimer’s Movement at Cleveland Clinic, the ...
- Planning ahead eases Alzheimer's moral and ethical challengeson April 29, 2024 at 3:31 am
The very nature of this debilitating brain disorder presents a host of moral and/or ethical challenges both for the affected individual and the caregiver. The point of diagnosis in one dilemma. Some ...
- Mike Martin family teams with Alzheimer's Project to honor legacy with Derby eventon April 29, 2024 at 2:26 am
Coach Martin’s family has teamed up with the Alzheimer’s Project to honor the legacy of Mike Martin and to help others faced with this challenge.
- Neuroscientists Warn of 'Cascading' Alzheimer's Risk From These Two Habitson April 27, 2024 at 6:59 am
The habits produce a "synergistic effect" on our risk of developing Alzheimer's Disease and general cognitive decline.
via Bing News
